Zimbabwe has declined a major US health deal worth 367 million US dollars (272 million pounds) over five years over Washington's request for confidential information.
This rejection became public following a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government representative has since stated that the United States was demanding access to biological samples for scientific study and commercial purposes but was unwilling to share the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more talks to find a deal agreeable to both sides so the nation's vital HIV programme can continue.
Broader Implications
This development comes after a similar situation in Kenya, where a court suspended a related health funding agreement after concerns were raised about the security of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral deals to boost openness and responsibility.
Based on reports, Sixteen African countries have so far signed similar agreements, constituting more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no equivalent assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would provide the basic resources for medical research without any certainty that the final treatments would be accessible to our citizens if a new pandemic emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of one-on-one health agreements were undermining systems previously established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This system is intended to ensure that when a nation contributes its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage further discussions with our American counterparts on how future co-operation could be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts said it understood the official position, but urged that talks should continue considering much of the nation's Aids initiatives relied on foreign aid.
"If technical issues arise, including those relating to information security or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," it added.
The situation emphasises the continuing debate between accepting crucial international aid and safeguarding a country's data in an increasingly interconnected world.